Mga Batayang Estadistika
| LEI | 529900KPTNUS5J8K9K66 |
| CIK | 1034842 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rigel Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 RIGEL PHARMACEUTICALS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-2 |
|
| August 5, 2025 |
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update · Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million · Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in p |
|
| August 5, 2025 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.2 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 5, 2025 |
Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended Exhibit 10.1 Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0- |
|
| May 6, 2025 |
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports First Quarter 2025 Financial Results and Provides Business Update · First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million · Generated $11.4 million of net income in the first quarter of 2025 · R289 granted Orphan Drug designation for the treatment of MDS |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| April 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| March 27, 2025 |
Exhibit 99.1 Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively “Annora”) resolving pat |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents kr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 4, 2025 |
Lease Agreement with 611 Gateway Center LP, dated February 25, 2025 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 4, 2025 |
Amendment No. 1 to Sublease Agreement with Atara Biotherapeutics, Inc., dated October 10, 2024 Exhibit 10.34 Amendment No. 1 to Sublease Agreement This Amendment No. 1 (“Amendment No. 1”) is made and effective the date of last signature below (“First Amendment Effective Date”) between Atara Biotherapeutics, Inc. (“Sublandlord”) and Rigel Pharmaceuticals, Inc. (“Subtenant”). Defined terms used but not otherwise defined herein have the meaning ascribed to them in the Sublease (as defined belo |
|
| March 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| March 4, 2025 |
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update · Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million · 2024 total revenue of approximately $179.3 million, which includes T |
|
| March 4, 2025 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 5th Amendment to the COLLABORATION AND LICENSE AGREEMENT This 5th Amendment to the COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of October 23, |
|
| March 4, 2025 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.9 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| March 4, 2025 |
Rigel Pharmaceuticals, Inc. Insider Trading Policy Exhibit 19.1 RIGEL PHARMACEUTICALS, INC. INSIDER TRADING AND WINDOW PERIOD POLICY ADOPTED AUGUST 15, 2018 AMENDED AND RESTATED MARCH 1, 2021 AMENDED AND RESTATED April 7, 2022 AMENDED AND RESTATED June 29, 2023 INTRODUCTION During the course of your relationship with Rigel Pharmaceuticals, Inc. (“Rigel”), you may receive material information that is not yet publicly available (“material nonpublic |
|
| March 4, 2025 |
Offer Letter from Rigel Pharmaceuticals, Inc. to Lisa Rojkjaer, M.D., dated December 20, 2023 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| January 13, 2025 |
Rigel Provides Business Update and 2025 Outlook Exhibit 99.1 Rigel Provides Business Update and 2025 Outlook · Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million · R289 granted Orphan Drug designation by the FDA for the treatment of MDS · Rigel anticipates 2025 total |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| December 9, 2024 |
Exhibit 99.1 Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition · R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients · RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, C |
|
| November 14, 2024 |
RIGL / Rigel Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* RIGEL PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 766559702 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 8, 2024 |
RIGL / Rigel Pharmaceuticals, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rigel Pharmaceuticals Inc (Name of Issuer) Common Stock (Title of Class of Securities) 766559702 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 8, 2024 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| November 7, 2024 |
Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd., dated September 3, 2024 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT by and between Rigel Pharmaceuticals, Inc., and KISSEI PHARMACEUTICAL CO., LTD. September 3, 2024 COLLABORATION AND LICENSE AGREEMENT This Collab |
|
| November 7, 2024 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 4th Amendment to the COLLABORATION AND LICENSE AGREEMENT This 4th Amendment to the COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is made and entered into as of September 3, |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| November 7, 2024 |
Supply Agreement with Kissei Pharmaceutical Co., Ltd., dated September 3, 2024 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY AGREEMENT This Supply Agreement (the “Supply Agreement”) is entered into as of September 3, 2024 (the “Effective Date”) by and between Rigel Pharmaceuticals, Inc., a Delaware |
|
| November 7, 2024 |
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update · Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million · Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indicatio |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commi |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| August 8, 2024 |
Rigel PHARMACEUTICALS, Inc. 611 Gateway Boulevard, Suite 900 South San Francisco, California 94080 (650) 624-1100 August 8, 2024 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Rigel Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-281230 Acceleration Request Req |
|
| August 6, 2024 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.2 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-2 |
|
| August 6, 2024 |
Calculation of Filing Fee Table. EX-FILING FEES Calculation of Filing Fee Table FORM S-8 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| August 6, 2024 |
Exhibit 10.1 Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
RIGEL PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Exhibit 99.1 Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Second quarter total revenue of $36.8 million, which includes TAVALISSE® net product sales of $26.4 million, REZLIDHIA® net product sales of $5.2 million and GAVRETO® net product sales of $1.9 million · Successfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic no |
|
| August 2, 2024 |
Calculation of Filing Fee Table EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| August 2, 2024 |
Exhibit 1.2 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM August 2, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of |
|
| August 2, 2024 |
As filed with the Securities and Exchange Commission on August 2, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 2, 2024 Registration No. |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| June 27, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RIGEL PHARMACEUTICALS, INC. RIGEL PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that: FIRST: The name of the Corporation is Rigel Pharmaceuticals, Inc. SECOND: The date on which t |
|
| June 25, 2024 |
Rigel Announces Reverse Stock Split Exhibit 99.1 Rigel Announces Reverse Stock Split SOUTH SAN FRANCISCO, Calif., June 25, 2024 /PRNewswire/ - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company’s common s |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 7, 2024 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. amendment No. 4 to CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 11th day of April, 2024, by and among R |
|
| May 7, 2024 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.4 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0- |
|
| May 7, 2024 |
Asset Purchase Agreement with Blueprint Medicines Corporation, dated February 22, 2024 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT between BLUEPRINT MEDICINES CORPORATION and RIGEL PHARMACEUTICALS, INC. DATED AS OF FEBRUARY 22, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND TERM |
|
| May 7, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 2 to the License and Collaboration Agreement This Amendment No. 2 to the License and Collaboration Agreement by and between Rigel Pharmaceuticals, Inc. (“Rigel”), and |
|
| May 7, 2024 |
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update · First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 million · Expanded Rigel's portfolio with acquisition of GAVRETO®, a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| April 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| March 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| March 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents kr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 5, 2024 |
Incentive Compensation Recoupment Policy (Clawback Policy), dated August 10, 2023. Exhibit 97 RIGEL PHARMACEUTICALS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.Adoption. The Compensation Committee of the Board of Directors, on behalf of the Board of Directors (the “Board”) of Rigel Pharmaceuticals, Inc. (the “Company”), has adopted this Incentive Compensation Recoupment Policy (the “Recoupment Policy”) to set forth the conditions under which the Company will seek reimbursem |
|
| March 5, 2024 |
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million · Expanded product portfolio with acquisition of U.S. rights to GAVRETO®, an FDA approved targeted therapy for the treatment of R |
|
| March 5, 2024 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.9 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| February 22, 2024 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| February 14, 2024 |
RIGL / Rigel Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
RIGL / Rigel Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Rigel Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 766559603 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RIGEL PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 766559603 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 8, 2024 |
Rigel Pharmaceuticals Provides Business Update Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million · Strategic alliance with MD Anderson to advance REZLIDHIA in AML and other cancers · Collaboration with CONNECT to evaluate REZLIDHIA in a Phas |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissi |
|
| November 30, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 7, 2023 |
Exhibit 10.1 RIGEL PHARMACEUTICALS, INC. AMENDED AND RESTATED EXECUTIVE SEVERANCE PLAN Section 1. Introduction. The Rigel Pharmaceuticals, Inc. Executive Severance Plan (the “Plan”) is established effective January 24, 2018, and amended and restated effective August 10, 2023. The purpose of the Plan is to provide for the payment of severance benefits to certain eligible executives of Rigel Pharmac |
|
| November 7, 2023 |
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net product sales of $2.7 million · New data on olutasidenib in mIDH1 relapsed or refractory acute myeloid leukemia to be presented at ASH Annual Meeting · Conference call |
|
| November 7, 2023 |
[*] = CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 1, 2023 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. Exhibit 10.2 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-2 |
|
| August 1, 2023 |
Exhibit 99.1 Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update · Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE® net product sales of $21.3 million and REZLIDHIA® net product sales of $2.6 million · Development programs continue to advance with completion of target enrollment in cohort 2 of Phase 1b trial of R289 in lower-risk MDS and ini |
|
| August 1, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| August 1, 2023 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 611 Gateway Boulevard, Suite 900 South |
|
| August 1, 2023 |
Exhibit 10.1 Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: |
|
| August 1, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMendment 1 to LICENSE AND TRANSITION SERVICES AGREEMENT This AMENDMENT 1 to the License and Transition Services Agreement by and between Rigel Pharmaceuticals, Inc. (the “Company” |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| May 2, 2023 |
Rigel Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports First Quarter 2023 Financial Results and Provides Business Update · First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE® net product sales of $22.3 million and REZLIDHIA® net product sales of $1.5 million · Global expansion of TAVALISSE in ITP with Japanese launch by partner Kissei · Conference call and webcast scheduled today at 4:30 p.m. Eastern |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0- |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| March 7, 2023 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. Exhibit 10.38 Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amended |
|
| March 7, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 7, 2023 |
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update ● Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million ● REZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines® for AML ● Confer |
|
| March 7, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 7, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 S-8 1 tm238716d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State or other jurisdiction of inco |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents kr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| February 22, 2023 |
EX-99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendmen |
|
| February 22, 2023 |
RIGL / Rigel Pharmaceuticals / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RIGEL PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 766559603 (CUSIP Number) February 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 14, 2023 |
RIGL / Rigel Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-rigl123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rigel Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 766559603 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2023 |
RIGL / Rigel Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Rigel Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 766559603 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| January 9, 2023 |
Rigel Pharmaceuticals Provides Business Update EX-99.1 2 tm232596d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update - REZLIDHIA™ U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation - Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million which includes TAVALISSE® preliminary net product sales of approx |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissi |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| December 2, 2022 |
Exhibit 99.1 Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML patients |
|
| November 29, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 3, 2022 |
Exhibit 10.1 ? ? ? ? ? ? ? ? ? ? ? ? ? LICENSE AND transition services AGREEMENT by and between RIGEL PHARMACEUTICALS, INC., and Forma Therapeutics, Inc. July 27, 2022 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENT |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| November 3, 2022 |
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update · FDA review ongoing for olutasidenib NDA; preparations underway for potential launch · Third quarter TAVALISSE® net product sales of $19.2 million and total revenues of $22.4 million · Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 3, 2022 /PRNewswi |
|
| November 3, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 3, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF RIGEL PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 2 Section 6. Special Meetings 2 Section 7. Notice Of Meet |
|
| November 1, 2022 |
Exhibit 99.1 Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients SOUTH SAN FRANCISCO, Calif., November 1, 2022 /PRNewswire/ - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety results from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respir |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| October 11, 2022 |
Exhibit 99.1 Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback -Announces Workforce Reduction- SOUTH SAN FRANCISCO, Calif., October 10, 2022 /PRNewswire/ - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)’s review of the Company’s re-analysis of data from the FORWARD Phase 3 tria |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| September 22, 2022 |
RIGL / Rigel Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RIGEL PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 766559603 (CUSIP Number) SEPTEMBER 16, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant |
|
| August 3, 2022 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 S-8 1 tm2222340d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State of Incorporation) (I.R.S. E |
|
| August 2, 2022 |
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update ● Second quarter TAVALISSE® net product sales of $18.6 million and total revenues of $29.8 million ● Expanded Rigel’s hematology-oncology portfolio by entering into an exclusive license agreement with Forma Therapeutics, Inc. for olutasidenib with an expected launch in 2023 ● Enrollment completed in Rigel |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-2 |
|
| August 2, 2022 |
Exhibit 10.1 Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders: |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| June 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| June 8, 2022 |
Exhibit 99.1 Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia Conference call and webcast to be held today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., June 8, 2022 /PRNewswire/ - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced top-line efficacy and safety data from the FORWARD Phase 3 clinic |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| May 3, 2022 |
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports First Quarter 2022 Financial Results and Provides Business Update ? First quarter TAVALISSE? net product sales of $16.2 million and total revenues of $16.7 million ? Topline data from FORWARD study, a pivotal, Phase 3 clinical trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA), on track for mid-2022 ? Management to host a conference call and webcast today |
|
| May 3, 2022 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended. Exhibit 10.2 ? Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amende |
|
| May 3, 2022 |
Exhibit 10.1 ? SIXTH AMENDMENT TO BUILD-TO-SUIT LEASE This SIXTH AMENDMENT TO BUILD-TO-SUIT LEASE (?Sixth Amendment?) is made and entered into as of March 21, 2022 (?Effective Date?), by and between HCP BTC, LLC, a Delaware limited liability company (?Landlord?), and RIGEL PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). r e c i t a l s : A.Landlord (as successor-in-interest to Slough BTC |
|
| April 5, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| April 5, 2022 |
DEFA14A 1 ny20002079x2defa14a.htm FORM DEFA14A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| March 1, 2022 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.31 ? Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amend |
|
| March 1, 2022 |
Exhibit 10.35 ? [***] = CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? ? amendment No. 2 to CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is made as of this 11th day of February, 2022, by and among RIGEL PHARMACEUTICALS, IN |
|
| March 1, 2022 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) RIGEL PHARMACEUTICALS, INC. |
|
| March 1, 2022 |
Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ? Fourth quarter total revenues of $20.4 million; full year total revenues of $149.2 million ? On track to report topline data from Phase 3 pivotal trials of fostamatinib in warm autoimmune hemolytic anemia (wAIHA) and COVID-19 in mid-2022 ? Rigel Phase 3 trial in high-risk patients with COV |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents kr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 1, 2022 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Rigel Pharmaceuticals, Inc. |
|
| March 1, 2022 |
March 1, 2022 (File No. 333-263187) S-8 1 tm227975d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333- UNITD STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State of Incorporation) (I.R.S. Empl |
|
| March 1, 2022 |
Exhibit 10.32 ? ? Rigel Pharmaceuticals, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of Rigel Pharmaceuticals, Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| March 1, 2022 |
Exhibit 10.34 ? [***] = CERTAIN MARKED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? amendment No. 1 to CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is made as of this 29th day of March, 2021, by and among RIGEL PHARMACEUTICALS, INC., a |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| February 10, 2022 |
RIGL / Rigel Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Rigel Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 766559603 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 28, 2022 |
Exhibit 10.1 2022 CASH INCENTIVE PLAN Purpose: The terms of the 2022 Cash Incentive Plan (the ?2022 Plan?) have been established to reward the executives and other employees of Rigel Pharmaceuticals, Inc. (the ?Company?) for assisting the Company in achieving its operational goals through exemplary performance. Under the 2022 Plan, cash bonuses, if any, will be based on the achievement of corporat |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| January 10, 2022 |
Rigel Pharmaceuticals Provides Business Update EX-99.1 2 tm222422d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update · TAVALISSE preliminary 2021 net product sales of approximately $63.0 million · Topline data from Phase 3 clinical trial in warm autoimmune hemolytic anemia (wAIHA) expected in mid-2022 · R289, a potent and selective IRAK1/4 inhibitor, to start open-label Phase 2 study in low-risk myeloid dyspla |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 15, 2021 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 2, 2021 |
Rigel Pharmaceuticals, Inc. Inducement Plan, as amended Exhibit 10.1 ? ? Rigel Pharmaceuticals, Inc. Inducement Plan Adopted by the Compensation Committee: October 10, 2016 Amended by the Compensation Committee: January 3, 2017 Amended by the Compensation Committee: August 16, 2017 Amended by the Compensation Committee: November 7, 2017 Amended by the Compensation Committee: December 23, 2017 Amended by the Compensation Committee: January 24, 2018 Amen |
|
| November 2, 2021 |
Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA), topline data expected mid-2022 - Rigel's Phase 3 trial in high-risk hospitalized patients with COVID-19 has enrolled ~210 patients - Net product sales of $16.0 million and total revenu |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 22 )* Rigel Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 766559603 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| August 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissi |
|
| August 13, 2021 |
Exhibit 99.1 Rigel Pharmaceuticals Provides Update on COVID-19 Program - FDA declines to issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults - - Rigel?s COVID-19 program continues to actively enroll patients and will provide a robust data set to support the potential benefits of fostamatinib in COVID-19 - SOUTH SAN FRANCISCO, Calif., August 13, 2 |
|
| August 3, 2021 |
Exhibit 10.2 ? RIGEL PHARMACEUTICALS, INC. 2000 EMPLOYEE STOCK PURCHASE PLAN Approved by the Board of Directors August 18, 2000 Approved by Stockholders September 11, 2000 Amended and Restated April 24, 2003 Approved By Stockholders June 20, 2003 Amended January 31, 2007 Approved by Stockholders May 31, 2007 Amended by the Compensation Committee November 13, 2008 Amended by the Compensation Commit |
|
| August 3, 2021 |
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update - Net product sales of $17.1 million and total revenues of $26.3 million - Rigel?s Phase 3 trial in patients with wAIHA has enrolled 80 patients - Rigel?s Phase 3 trial in high-risk hospitalized patients with COVID-19 has enrolled ~150 patients - Fostamatinib selected for NIH ACTIV-4 trial in hospitalized |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 3, 2021 |
Exhibit 10.1 ? Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23,2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 Amended January 28, 2021 Amended March 9, 2021 Approved by the Stockholders |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 3, 2021 |
S-3ASR 1 tm2123719-1s3asr.htm S-3ASR TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 3, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 94-3248524 (State |
|
| August 3, 2021 |
Exhibit 4.6 RIGEL PHARMACEUTICALS, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) 102 (c)(2) 102 (e) 102 Sec. 315(b) 601 Sec. 316(a) (last sentence) 101 (?Outstanding?) (a)(1)(A) Article 5 (a)(1)(B) Article 5 (b) Article 5 (c) 104(c) Sec. |
|
| June 21, 2021 |
June 21, 2021 (File No. 333-257226) S-8 1 tm2120174d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 21, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State or other jurisdiction of Inc |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 5, 2021 |
Non-employee Directors’ Compensation Policy Exhibit 10.2 ? ? Rigel Pharmaceuticals, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of Rigel Pharmaceuticals, Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| May 5, 2021 |
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports First Quarter 2021 Financial Results and Provides Business Update - Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19 - Net product sales of $12.4 million and total revenues of $81.0 million - Received upfront cash payment of $125 million from Eli Lilly for the exclusive license agreement for Rigel?s RIP1 i |
|
| May 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| May 5, 2021 |
[*] = Certain marked information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| April 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| April 13, 2021 |
Exhibit 99.1 Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 Broad and consistent improvement in clinical outcomes including serious adverse events, mortality, ordinal scale assessment and number of days in the ICU Rigel plans to share these results with health authorities, including the US FDA Conference ca |
|
| April 6, 2021 |
definitive proxy statement on Schedule 14A, filed with the SEC on April 6, 2021 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as per |
|
| March 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| March 2, 2021 |
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel’s RIP1 inhibitor program - Launched a Phase 3 clinical trial of fostamatinib i |
|
| March 2, 2021 |
Table of Contents rkr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 18, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) RIGEL PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 766559603 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Rigel Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 766559603 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 4, 2021 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 21 )* Rigel Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 766559603 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| February 3, 2021 |
EX-10.1 2 tm214981d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 2021 CASH INCENTIVE PLAN Purpose: The terms of the 2021 Cash Incentive Plan (the “2021 Plan”) have been established to reward the executives and other employees of Rigel Pharmaceuticals, Inc. (the “Company”) for assisting the Company in achieving its operational goals through exemplary performance. Under the 2021 Plan, cash bonuses, if any, |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| January 11, 2021 |
Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update TAVALISSE® preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41% U.S. FDA awards Fast Track designation to TAVALISSE® for warm autoimmune hemolytic anemia Topline data from NIH Phase 2 clinical trial in COVID-19 expected in April ‘21 SOUTH SAN FRANCISCO, Calif., January 11, 2021 /PRNewswire/ - |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| November 5, 2020 |
Exhibit 99.1 Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update Third quarter total revenues of $18.4 million Net product sales of $16.3 million, a 39% year-over-year increase Launching Phase 3 clinical trial of fostamatinib in COVID-19 patients Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, Calif., November 5, 2020 /PRNewswire/ - Rigel P |
|
| November 5, 2020 |
Exhibit 10.1 [***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. July 13, 2020 David Santos [***] Re: Offer and Employment Terms Dear David: Rigel Pharmaceuticals, Inc. (the Company) is pleased to offer you the position of Executive Vice President and C |
|
| October 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissi |
|
| August 4, 2020 |
EX-1.1 2 rigl-20200630xex1d1.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 4, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (th |
|
| August 4, 2020 |
424B5 1 a2242182z424b5.htm 424B5 Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223564 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED APRIL 2, 2018) $65,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating t |
|
| August 4, 2020 |
August 4, 2020 (File No. 333-240371) As filed with the Securities and Exchange Commission on August 4, 2020 Registration No. |
|
| August 4, 2020 |
Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended. Exhibit 10.1 Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan Adopted by the Board of Directors: February 1, 2018 Approved by the Stockholders: May 16, 2018 Amended January 23, 2019 Amended January 31, 2019 Approved by the Stockholders: May 22, 2019 Amended February 3, 2020 Approved by the Stockholders: May 14, 2020 1.General. (a)Successor to and Continuation of Prior Plans. The Plan is inte |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 4, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-2 |
|
| August 4, 2020 |
Exhibit 99.1 Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper- inflammatory response to serum from severe COVID-19 patients Appointed 30-year industry veteran David Sant |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission |
|
| May 5, 2020 |
Exhibit 99.1 Rigel Reports First Quarter 2020 Financial Results and Provides Business Update First quarter net product sales of $12.7 million and collaboration revenues of $43.1 million 41 patients enrolled in pivotal Phase 3 clinical trial in warm AIHA Received $10.0 million in funding from existing credit facility Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, Cali |
|
| May 5, 2020 |
Executive Severance Plan as amended EX-10.1 2 rigl-20200331ex1019ed5fb.htm EX-10.1 Exhibit 10.1 Approved by the Board of Directors on February 6, 2020 RIGEL PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE PLAN Section 1. Introduction. The Rigel Pharmaceuticals, Inc. Executive Severance Plan (the “Plan”) is established effective January 24, 2018. The purpose of the Plan is to provide for the payment of severance benefits to certain eligibl |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commission F |
|
| May 5, 2020 |
Table of Contents s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 1, 2020 |
QuickLinks - Click here to rapidly navigate through this document United States Securities and Exchange Commission Washington, D. |
|
| April 1, 2020 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2020 |
RIGL / Rigel Pharmaceuticals, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 27, 2020 |
RIGL / Rigel Pharmaceuticals, Inc. 10-K - Annual Report - 10-K Table of Contents rkr UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| February 27, 2020 |
[***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| February 27, 2020 |
EX-4.1 2 rigl-20191231ex41b54a47f.htm EX-4.1 Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK References herein to “Rigel,” “our,” “we,” “us” and the “Company” refer only to Rigel Pharmaceuticals, Inc. General Our authorized capital stock consists of 400,000,000 shares of common stock, $0.001 par value per share, or common stock, and 10,000,000 shares of preferred stock, $0.001 par value per share, or pre |
|
| February 27, 2020 |
Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Fourth quarter total revenues of $15.4 million; full year total revenues of $59.3 million Fourth quarter net product sales of $13.8 million; full year net product sales of $43.8 million Received $20.0 million payment from Grifols in first quarter 2020 for European approval of fostamatinib in |
|
| February 14, 2020 |
RIGL / Rigel Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) RIGEL PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 766559603 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| February 11, 2020 |
RIGL / Rigel Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Rigel Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 766559603 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| January 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 20 )* Rigel Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 766559603 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 13, 2020 |
Rigel Pharmaceuticals Provides Business Update Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update - TAVALISSE® preliminary 4Q net product sales of approximately $13.8 mln, YoY increase of 90%; preliminary 4Q total revenues of approximately $15.4 mln - Received European approval of fostamatinib disodium hexahydrate for adult patients with chronic ITP - Phase 3 pivotal trial for warm AIHA on track with 20 patients enrolled, including 15 |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| December 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 22, 2019 |
Exhibit 10.1 2020 CASH INCENTIVE PLAN Purpose: The terms of the 2020 Cash Incentive Plan (the “2020 Plan”) have been established to reward the executives and other employees of Rigel Pharmaceuticals, Inc. (the “Company”) for assisting the Company in achieving its operational goals through exemplary performance. Under the 2020 Plan, cash bonuses, if any, will be based on the achievement of corporat |
|
| November 18, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commis |
|
| November 18, 2019 |
Exhibit 99.1 Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe SOUTH SAN FRANCISCO, November 15, 2019 /PRNewswire/— Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has a |
|
| November 14, 2019 |
RIGL / Rigel Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RIGEL PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 766559603 (CUSIP Number) NOVEMBER 8, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| November 5, 2019 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE RIGEL PHARMACEUTICALS, INC. HAS DETERMINED THE INFORMATION (II) IS NOT MATERIAL AND (II) WOULD LIKLEY CAUSE COMPETITIVE HARM TO RIGEL PHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED. CREDIT AND SECURITY AGREEMENT dated as of September 27, 2019 by and among RIGEL PHARMACEUTICALS, INC., as |
|
| November 5, 2019 |
RIGL / Rigel Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 5, 2019 |
Exhibit 99.1 Rigel Announces Third Quarter 2019 Financial Results Net sales of TAVALISSE® increased 15% quarter over quarter to $11.7 million Advances development pipeline with new RIP1 inhibitor program initiating a Phase 1 study and positive in-human data from IRAK1/4 inhibitor program Conference call and webcast today at 4:30pm Eastern Time SOUTH SAN FRANCISCO, Calif., November 5, 2019 /PRNewsw |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commiss |
|
| October 23, 2019 |
Exhibit 99.2 Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe SOUTH SAN FRANCISCO, October 18, 2019 /PRNewswire/— Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a posi |
|
| October 23, 2019 |
Exhibit 99.1 Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call TAVALISSE® net product sales increased 15% quarter over quarter to $11.7 million Positive results from IRAK1/4 Proof-of-Mechanism study in humans Announced new RIP1 inhibitor program, lead molecule enters Phase 1 clinical trial Appoints Wolfgang Dummer, MD, PhD as Chief Medical Officer Investor/analyst con |
|
| October 23, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-29889 94-3248524 (State or other jurisdiction of incorporation) (Commi |
|
| October 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commi |
|
| August 7, 2019 |
August 7, 2019 (File No. 333-233064) As filed with the Securities and Exchange Commission on August 7, 2019 Registration No. |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 0-29889 94-3248524 (Commissio |
|
| August 6, 2019 |
Exhibit 99.1 Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call and webcast today at 4:30PM Eastern Time SOUTH SAN FRANCISCO, August 6, 2019 /PRNewswire/— Rigel Pharm |
